# A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

> **NCT03149003** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 221 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** DSP-7888 Dosing Emulsion
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03149003
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-08
- **Primary completion:** 2021-08-30
- **Final completion:** 2021-08-30
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03149003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03149003, "A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03149003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*